A reciprocal translocation occurring when the abl gene from chromosome 9 joins with the bcr gene from chromosome 22 to form the hybrid bcr/abl gene. This abnormal gene is almost always found in patients with Chronic Myelogenous Leukemia (CML). It also occurs in adults and children with Acute Lymphocytic Leukemia (ALL). When found in ALL, the patient has a poor prognosis.
Characteristic chromosomal abnormality in which a portion of chromosome 22 is translocated to chromosome 9. The mutation results in a fused BCR-ABL gene, which encodes the Bcr-Abl tyrosine kinase believed to be responsible for causing chronic myelogenous leukemia. The Philadelphia chromosome is found in virtually all cases of chronic myelogenous leukemia and some cases of acute lymphoblastic leukemia.
An abnormal chromosome that is formed when part of chromosome 9 attaches to chromosome 22 (translocation). This abnormality is found in nearly all cases of chronic myeloid leukemia. Also called as Ph1.
An abnormality of chromosome 22 characterized by shortening of its long arms (the missing portion usually translocated to chromosome 9) and present in marrow cells of most patients with chronic myelocytic leukemia.
An abnormal chromosome, which is responsible for the constant production of abnormal white blood cells (myeloid cells) that are present in CML.
A abnormality of chromosome 22 that is seen in the bone marrow and blood cells of most patients with chronic myelogenous leukemia and some with acute lymphocytic leukemia. Also called Ph1.
An abnormality of chromosome 22 in which part of chromosome 9 is transferred to it. Bone marrow cells that contain the Philadelphia chromosome are often found in chronic myelogenous leukemia.
A chromosomal abnormality found in the hematopoeitic cells of most patients with chronic myelogenous leukemia and in some patients with acute lymphoblastic leuk...
The hallmark of CML. This is the term used to describe the abnormal appearing human chromosome 22, which is found in 95 percent of people who have CML. It results from a mutation that involves the swapping of genetic material between chromosomes 9 and 22 (see bcr-abl). If you have this chromosome, you are considered Ph+, or Ph-positive. If you don't, you are Ph-, or Ph-negative. The proportion of Ph+ to Ph- cells is used to track progress in treating CML: If the number of Ph+ chromosomes decreases at all during treatment, you have achieved a cytogenetic response (CR); if your Ph+ percentage drops to 35 percent or less, it is considered a major cytogenetic response (MCR); 0% Ph+ is a complete cytogenetic response (CCR).
an abnormally short chromosome (number 22), usually referred to as the Ph-chromosome
translocation between the long arms of chromosomes 9 and 22, often found in the white blood cells of patients with chronic myeloid leukemia.
Philadelphia chromosome or Philadelphia translocation is a specific chromosomal abnormality that is associated with chronic myelogenous leukemia (CML). It is due to a reciprocal translocation, an exchange of genetic material, between chromosomes 9 and 22. The presence of this translocation is a highly sensitive test for CML, since 95% of people with CML have this abnormality (The remainder have either a cryptic translocation that is invisible on G-banded chromosome preparations, or a variant translocation involving another chromosome or chromosomes as well as the long arm of chromosomes 9 and 22).